Inspira Technologies OXY B.H.N. (NASDAQ:IINN) versus Elekta (OTCMKTS:EKTAY) Head-To-Head Contrast

Elekta (OTCMKTS:EKTAY) and Inspira Technologies OXY B.H.N. (NASDAQ:IINN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Profitability

This table compares Elekta and Inspira Technologies OXY B.H.N.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elekta	1.15%	11.55%	3.75%
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A

Insider & Institutional Ownership

12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. 41.3% of Elekta shares are held by insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Elekta and Inspira Technologies OXY B.H.N.”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elekta	$1.71 billion	1.15	$22.37 million	$0.05	102.48
Inspira Technologies OXY B.H.N.	N/A	N/A	-$11.05 million	N/A	N/A

Elekta has higher revenue and earnings than Inspira Technologies OXY B.H.N..

Risk & Volatility

Elekta has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Elekta and Inspira Technologies OXY B.H.N., as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elekta	0	2	0	0	2.00
Inspira Technologies OXY B.H.N.	0	0	1	0	3.00

Inspira Technologies OXY B.H.N. has a consensus price target of $2.00, indicating a potential upside of 127.32%. Given Inspira Technologies OXY B.H.N.’s stronger consensus rating and higher probable upside, analysts plainly believe Inspira Technologies OXY B.H.N. is more favorable than Elekta.

Summary

Elekta beats Inspira Technologies OXY B.H.N. on 6 of the 11 factors compared between the two stocks.

About Elekta

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

About Inspira Technologies OXY B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.